University of New Mexico

UNM Digital Repository
NotiSur

Latin America Digital Beat (LADB)

6-8-1995

Argentine President, Congress Locked in Battle
Over New Patent Law
LADB Staff

Follow this and additional works at: https://digitalrepository.unm.edu/notisur
Recommended Citation
LADB Staff. "Argentine President, Congress Locked in Battle Over New Patent Law." (1995). https://digitalrepository.unm.edu/
notisur/11935

This Article is brought to you for free and open access by the Latin America Digital Beat (LADB) at UNM Digital Repository. It has been accepted for
inclusion in NotiSur by an authorized administrator of UNM Digital Repository. For more information, please contact amywinter@unm.edu.

LADB Article Id: 56071
ISSN: 1060-4189

Argentine President, Congress Locked in Battle Over New
Patent Law
by LADB Staff
Category/Department: Argentina
Published: 1995-06-08
In mid-May, the Argentine Senate overrode President Carlos Menem's recent decision to partially
veto a new intellectual property rights law that would extend patent protection to pharmaceutical
products. Intense negotiations are now underway between the executive and the Chamber of
Deputies, where a majority of legislative representatives say they will ratify the Senate decision.
Nevertheless, the president has vowed to maintain his veto by executive decree if necessary,
foreshadowing a lengthy legal battle that may ultimately have to be resolved by the Supreme Court.
In late April, President Menem vetoed 16 clauses contained in a proposed intellectual property
rights law that Congress had approved on March 30.
Essentially, the bill would have extended patent protection to pharmaceutical products, since
the country's century-old patent-rights law does not cover medicines. Nevertheless, the US, the
European Union (EU), and some other countries mounted an intense lobby to block the bill's
approval (see NotiSur, 04/27/95). Foreign governments and drug companies argued that the bill
contained measures that would in effect continue to protect domestic industries from foreign
competition, thus constituting unfair trade practices that would violate international agreements on
patent rights contained in the General Agreement on Tariffs and Trade (GATT). In particular, the
critics objected to two clauses: first, a stipulation that prohibits patents for imported drugs, thereby
forcing multinationals to set up local operations in Argentina to qualify for patent protection;
and second, an eight-year grace period before the new patent law takes effect, thus allowing
domestic drug companies to continue to market bootlegged products until the year 2003. The latter
clause is particularly controversial because the US and the EU claim it violates GATT accords on
pharmaceutical products.
GATT rules allow "least developed countries" (LDC) a ten-year transition period for domestic
industries to modernize before being forced to compete openly with the multinationals. But the
Argentine pharmaceutical industry which markets its products in Europe and other countries is
estimated to be the thirteenth largest in the world. Thus, the US and the EU argue that Argentina
cannot qualify for the LDC status, and must therefore impose patent legislation immediately.
Nevertheless, the international pressures to veto the law generated a nationalist reaction in the
legislature, where representatives accused the Menem administration of placing the interests of
foreign drug companies above that of domestic industries and consumers.
Even influential members of the governing Partido Justicialista (PJ) opposed the executive, arguing
that weak domestic businesses must be granted a reasonable transition period to modernize their
operations to compete on the open market, thereby avoiding massive layoffs in the pharmaceutical
industry. "In its original form, the bill reflects an attempt by Congress to strike a balance among
opposing interests," said Jorge Matzkin, head of the PJ bloc of representatives in the Chamber
of Deputies, where the governing party controls 100 of 254 seats."The bill will ensure respect
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for intellectual property rights and international treaties, but it will also protect the rights of our
businesses, workers, and consumers."
On May 17, the Senate where the PJ controls 30 of 48 seats unanimously voted to override 10 of
President Menem's 16 vetoes. In an attempt to reconcile some differences with the executive and
foreign governments, the Senate did agree to eliminate from the bill the stipulation that foreign
companies must set up operations in the country, thereby allowing multinationals to import their
products. But the Senate maintained intact the eight-year grace period before patent rights are to be
granted. The bill is now under debate in the Chamber of Deputies, where, by nearly all counts, the
Senate decision to reject Menem's vetoes will easily win approval once it is put to a vote. As a result,
an intense lobby is underway in the Chamber, where so far all efforts to negotiate a compromise on
the grace period have failed.
Executive and legislative representatives are considering a possible reduction in the transition
period from eight to five years, which a majority of Chamber representatives would apparently
support. Nevertheless, the Menem administration which is under intense pressure from the US and
foreign drug companies is divided over the issue, and so far hard-line positions have dominated in
the cabinet. "Any grace period that stretches beyond one year would be an atrocity," said Economy
Minister Domingo Cavallo, one of the most influential members of the Menem cabinet who has
argued for full patent rights to take effect no later than Jan. 1, 1996. "The country must protect
intellectual property rights because it is the only way fresh capital will enter the country, without
which we won't have the financial means necessary to produce new products on our own. I firmly
believe in the scientific capabilities of Argentines, and I think we have scientists who are quite
capable of making their own discoveries, without copying from others."
The crux of the debate is whether the grace period constitutes a violation of GATT accords. Despite
the claim by foreign governments that Argentina does not qualify for LDC status, Argentine
legislators and domestic drug companies insist that the GATT stipulation of a ten-year transition
period to liberalize markets by approving new intellectual property rights laws represents a
deliberate concession to all developing countries, without exception. According to the legislators,
during the Uruguay Round negotiations, Argentina and other developing nations fought for a
lengthy transition period to approve patent laws in exchange for their willingness to accept a similar
grace period for the advanced industrialized countries to slowly phase out agricultural subsidies that
protect local farmers in those nations (see NotiSur, 09/30/93).
"It was very clear during the Uruguay Round negotiations that the developed countries would
be given ten years to reduce their agricultural subsidies by 36%, and in exchange the developing
countries would be granted ten years to comply with intellectual property rights," said Jorge
Matzkin. "Even Carla Hills, the US Trade Representative at that time, clearly stated that was the
spirit of the accord. In fact, in the patent bill for pharmaceuticals, we have only stipulated an eightyear transition period, so we have not violated the GATT accords in any way." Nevertheless,
President Menem adamantly supports the US and EU position, and he argues that Argentina's
endorsement of the GATT accords will allow him to ignore the legislature's override of his veto.
According to Menem, because the legislature approved the GATT treaty that came out of the
Uruguay Round, that international treaty now takes precedence over national laws, allowing Menem
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to simply amend the patent bill through executive decree under the justification that the president is
intervening to avoid a breach of international law.
"In my view, since the GATT accords have taken effect and since the executive is empowered with
enforcing those accords, the solution to the problem is evident," said Menem. "I only intend to
take into account the GATT legislation, which was approved by our parliament. Any other law
that comes out of the legislature is inferior to the international agreements contained in GATT."
Since Menem has vowed to uphold his veto through executive decree regardless of the outcome of
the vote in the Chamber of Deputies, the affair may ultimately be left up to the Supreme Court to
resolve, since legislative representatives say the president's position is unconstitutional.
"Menem is exercising powers that he does not have," said ex-president Raul Alfonsin, head of
the opposition Radical Party, which controls 84 of the 254 Chamber seats and 10 of the 48 Senate
seats. "The executive is illegally pushing the bill forward, since it is against the constitution for
the president to exercise legislative functions." [Sources: La Jornada (Mexico), 04/06/95; Journal
of Commerce, 04/21/95, 04/28/95; Associated Press, 05/05/95; United Press International, 04/24/95,
04/27/95, 04/28/95, 05/23/95; Reuter, 04/27/95, 05/23/95; Agence France-Presse, 05/17/95, 05/18/95,
05/20/95, 05/22/95, 05/23/95, 05/29/95, 05/31/95, 06/01/95, 06/04/95]
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